Cleveland Clinic Abu Dhabi launches world’s first clinical AI scientist
Aila platform transforms real patient data into real-time clinical decisions
#UAE #healthcare – Cleveland Clinic Abu Dhabi, the number one hospital in the UAE as ranked in the Newsweek’s 2026 World’s Best Hospitals list, has announced a collaboration with AI biotech company Owkin to launch the world’s first ‘clinical AI scientist’. Aila, an advanced clinical AI platform, is built on Owkin’s agentic K Pro biology platform and is designed to reason across complex clinical datasets, generate actionable medical insights in real time. The platform is built to continuously learns from patient data. The initial deployment focuses on prostate cancer, integrating electronic health records, physician notes, pathology reports and medical imaging into a unified, queryable knowledge layer available at the point of care.
SO WHAT? – Clinical decision-making has always been constrained by the time it takes to assemble and interpret data from multiple sources. Aila is designed to collapse that timeline from days or weeks to real time, providing clinicians access to insights derived from the full complexity of a patient’s data precisely when decisions must be made. If the platform delivers on its design, this could have a significant impact on patient experience, the workflow of clinicians and even patient outcomes.
KEY POINTS:
Cleveland Clinic Abu Dhabi and Owkin have launched Aila, as the ‘world’s first clinical AI scientist’. The platform is designed to reason across complex datasets, generate actionable medical insights and continuously learn. Aila is built to function as an active scientific collaborator rather than a passive analytical tool.
Aila operates through a secure, natural-language interface, allowing physicians to query vast amounts of clinical data in real time and receive insights that previously took days or weeks of manual analysis. The platform’s primary goal is to transforms fragmented clinical information into a unified, queryable knowledge layer available at the critical moment of decision-making.
The initial deployment focuses on prostate cancer, integrating multiple clinical data sources including electronic health records, physician notes, pathology reports and medical imaging. The multi-source integration is central to Aila’s value proposition — connecting data that typically exists in silos across a patient’s clinical history.
Aila is built on Owkin’s agentic K Pro platform, which is designed for biology and engineered to scale across additional medical specialities and increasingly complex data modalities. Over time the platform will be able to incorporate advanced data types including multiomics and genomic data, supporting large-scale precision medicine initiatives.
The platform is supported by the UAE’s AI-enabled infrastructure, positioning Abu Dhabi’s healthcare ecosystem as the launch environment for a globally significant clinical AI deployment. Cleveland Clinic Abu Dhabi’s status as the region’s top-ranked hospital adds both credibility and scale to the initial rollout.
Aila forms part of Owkin’s broader vision to build thousands of AI scientists working continuously to accelerate medical breakthroughs, effectively compressing decades of biological discovery into years. The company’s model is built on exclusive partnerships with world-class hospitals, unique longitudinal patient datasets and automated laboratory infrastructure.
Owkin’s platform is built as a closed-loop reasoning system, trained natively on patient-level multimodal data and reinforced through real biological feedback. So the system continuously improves itself through clinical use rather than requiring periodic manual retraining.
Cleveland Clinic Abu Dhabi is a 394-bed facility with 15 institutes providing multidisciplinary care across complex and critical conditions. As an extension of the US-based Cleveland Clinic model, it brings both international clinical standards and deep regional patient data to the Aila deployment.
ZOOM OUT – A joint venture between the US-based Cleveland Clinic and Abu Dhabi sovereign investor Mubadala Investment Company, Cleveland Clinic Abu Dhabi is one of the region’s most credentialled and technologically savvy medical institutions. Spread over 442,681 square meters, the facility has a capacity of 490 beds and houses more than 50 medical and surgical subspecialties. Served by western board-certified physicians and multidisciplinary teams, the hospital has institutes covering cancer, neurology, cardiac and thoracic care, digestive disease and more. It has ranked as the top UAE hospital in Newsweek’s World’s Best Hospitals list from 2022 to 2026, and as one of the World’s Best Smart Hospitals from 2022 to 2026.
[Written and edited with the assistance of AI]
Source: Cleveland Clinic
Read more stories mentioning Cleveland Clinic Abu Dhabi:
Abu Dhabi launches AI-driven Life Sciences cluster (Middle East AI News)
Cleveland Clinic & G42 to identify AI opportunities (Middle East AI News)